- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00911612
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)? (welchol)
A Phase IIB Study to Evaluate the Effects of Welchol (Colesevelam Hydrochloride) on Colonic Transit, Intestinal Permeability and Bowel Function in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)
Our hypothesis is that the medication approved for treatment of high blood cholesterol levels, Colesevelam HCl (WELCHOL), decreases colonic transit and permeability in patients with diarrhea due to irritable bowel syndrome.
This effect is thought to result from the effect of the medication on bile acids, which can cause diarrhea.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population, about 5% having predominant diarrhea; current treatment is suboptimal as it may not be tolerated, lead to side effects or insufficient benefit. Bile acid malabsorption (BAM) is recognized as a cause of chronic diarrhea and has been investigated as a mechanism for the phenotype of diarrhea predominant IBS (D-IBS). Increased exposure of the colon to bile acids which may result from accelerated small bowel transit or abnormal function of the apical sodium bile acid transporter (ASBT) has been postulated to cause functional diarrhea or symptoms of D-IBS by a number of mechanisms, such as increase colonic secretion, and mucosal permeability. Recent preliminary data suggest that doses of chenodeoxycholate (CDC) that are approved for the dissolution of gall stones are associated with accelerated colonic emptying and looser stool consistency.
Hypothesis:
The bile acid binding agent, Colesevelam HCl, decreases colonic transit and permeability in patients with D-IBS.
Specific Aim:
To investigate the effect of Colesevelam, which binds bile acids in the small intestine and reduces the concentration of bile acids in the colon, on colonic transit, permeability and the bowel function of patients with D-IBS.
Methods:
Twenty-four D-IBS participants will be randomized to placebo or treatment with Welchol (Colesevelam HCL) 1.875 gram b.i.d. for 12-14 days. A baseline colon transit, 24 hour urine for colon permeability, and blood for serum 7 alpha-hydroxy-4-cholesten-3-one (7 alpha-HCO) will be measured and venous blood DNA will be collected and stored. The measurement of serum 7 alpha-hydroxy-4-cholesten-3-one (7 alpha-HCO), which is a measurement of hepatic cholesterol synthesis, is closely related to the fecal loss of bile acids, and is a validated method for screening for BAM. Following treatment for 12 days, transit and permeability studies will be repeated. Bowel function symptoms will be recorded for the duration of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with D-IBS
- Aged 18-65 years
- No abdominal surgery (except appendectomy or cholecystectomy as long as patients IBS-diarrhea symptoms preceded the cholecystectomy
Exclusion Criteria:
- Participants with known chronic liver disease or Aspartate aminotransferase (AST) or Alanine transaminase (ALT) > 2.0 X upper limit of normal
- Hypertriglyceridemia and pancreatitis by history
- Diabetes or hypoglycemia
- Significant coagulation disorder
- History of bowel obstruction
- Serum triglycerides >500 mg/dL
- History of vitamin A, D, E, or K deficiencies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Colesevelam
Participants received colesevelam 1.875 g twice daily
|
Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
Other Names:
|
Placebo Comparator: Placebo
Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
|
Inert capsule matching the study drug, given twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colonic Transit, Geometric Center at 24 Hours
Time Frame: After 12-14 days treatment
|
The scintigraphic method is used to measure colonic transit.
An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule.
Anterior and posterior gamma images are taken hourly.
The geometric center (GC) is the weighted average of counts in the different colonic regions.
The scale ranges from 1 to 5; a high GC implies faster colonic transit.
A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.
|
After 12-14 days treatment
|
Ascending Colon Emptying T1/2
Time Frame: After 12-14 days' treatment
|
The half time for the ascending colon emptying (T1/2) was measured by the scintigraphic method.
An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule that is swallowed by the subject.
Anterior and posterior gamma images are taken hourly.
From the hourly scans, a time-activity curve is plotted using linear interpolation between time points when content was measured.
The time taken to empty 50% of the isotope from the ascending colon is read from this time-activity curve.
|
After 12-14 days' treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colonic Permeability as Measured by Cumulative Urinary Excretion of Mannitol 8-24 Hours
Time Frame: after 12-14 days' treatment
|
Colonic permeability is measured through differential excretion of urine saccharides.
The subject ingests a methacrylate-coated capsule that contains saccharides (mannitol 1g and lactulose 5 g powder).
The capsule provides a means to protect the sugars from absorption, until the sugars are delivered to the colon by means of a standard delayed release capsule.
The value reported is the mean for each arm of the total amount of mannitol excreted over the 8-24 hour time period.
|
after 12-14 days' treatment
|
Colonic Transit, Geometric Center at 48 Hours
Time Frame: After 12-14 days' treatment
|
The scintigraphic method is used to measure colonic transit.
An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule.
Anterior and posterior gamma images are taken hourly.
The geometric center (GC) is the weighted average of counts in the different colonic regions.
The scale ranges from 1 to 5; a high GC implies faster colonic transit.
A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.
|
After 12-14 days' treatment
|
Stool Consistency
Time Frame: After 12-14 days' treatment
|
The subjects rated their stool consistency using the Bristol Stool Scale.
The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types.
Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.
|
After 12-14 days' treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Fernandez-Banares F, Esteve M, Salas A, Alsina M, Farre C, Gonzalez C, Buxeda M, Forne M, Rosinach M, Espinos JC, Maria Viver J. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol. 2007 Nov;102(11):2520-8. doi: 10.1111/j.1572-0241.2007.01438.x. Epub 2006 Aug 4.
- Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R, Zinsmeister AR. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010 Feb;8(2):159-65. doi: 10.1016/j.cgh.2009.10.020. Epub 2009 Oct 30.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Disease
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Colonic Diseases, Functional
- Colonic Diseases
- Intestinal Diseases
- Syndrome
- Irritable Bowel Syndrome
- Diarrhea
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Colesevelam Hydrochloride
Other Study ID Numbers
- 08-007454
- R01DK054681 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on Colesevelam
-
Daiichi Sankyo, Inc.CompletedType 2 Diabetes Mellitus | Hypercholesterolemia | Pre-diabetesUnited States, Colombia, India, Mexico
-
Seattle Institute for Biomedical and Clinical ResearchVA Puget Sound Health Care SystemCompletedPrediabetes | Impaired Fasting Glucose
-
University of Colorado, DenverDaiichi Sankyo, Inc.CompletedDiabetes Mellitus, Type 1 | HyperlipidemiasUnited States
-
Daiichi Sankyo, Inc.Completed
-
Daiichi Sankyo, Inc.CompletedType 2 DiabetesUnited States, Peru, Mexico
-
University Hospital, Gentofte, CopenhagenCompleted
-
Daiichi Sankyo, Inc.CompletedType 2 DiabetesUnited States
-
KineMedUniversity Medical Center Groningen; Daiichi Sankyo, Inc.; Diabetes & Glandular...CompletedType 2 Diabetes Mellitus | Impaired Glucose ToleranceUnited States
-
Daiichi Sankyo, Inc.CompletedType 2 DiabetesUnited States, Peru, Mexico
-
Foundation for Liver ResearchCompleted